Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.
2.

Clopidogrel and proton pump inhibitors--where do we stand in 2012?

Drepper MD, Spahr L, Frossard JL.

World J Gastroenterol. 2012 May 14;18(18):2161-71. doi: 10.3748/wjg.v18.i18.2161. Review.

3.

Anti-platelet therapy and managing ulcer risk.

Chan FK.

J Gastroenterol Hepatol. 2012 Feb;27(2):195-9. doi: 10.1111/j.1440-1746.2011.07029.x.

PMID:
22142030
4.

Proton pump inhibitors and clopidogrel.

Gaglia MA Jr, Waksman R.

Cardiovasc Ther. 2010 Jun;28(3):169-76. doi: 10.1111/j.1755-5922.2010.00143.x. Epub 2010 Mar 25. Review.

PMID:
20345494
5.

[Dilemma between gastroprotection and cardiovascular prevention].

Venerito M, Kandulski A, Malfertheiner P.

Dtsch Med Wochenschr. 2010 Nov;135(44):2193-8. doi: 10.1055/s-0030-1267498. Epub 2010 Oct 26. Review. German.

PMID:
20979006
7.

Proton pump inhibitor and clopidogrel interaction: fact or fiction?

Laine L, Hennekens C.

Am J Gastroenterol. 2010 Jan;105(1):34-41. doi: 10.1038/ajg.2009.638. Epub 2009 Nov 10. Review.

PMID:
19904241
8.

Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling.

Johnson DA, Chilton R, Liker HR.

Postgrad Med. 2014 May;126(3):239-45. doi: 10.3810/pgm.2014.05.2772.

PMID:
24918808
9.

Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians.

Tran M, Tafreshi J, Pai RG.

J Cardiovasc Pharmacol Ther. 2010 Dec;15(4):326-37. doi: 10.1177/1074248410369109. Epub 2010 Oct 11. Review.

PMID:
20938037
10.

Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.

Dunn SP, Steinhubl SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ.

J Am Heart Assoc. 2013 Jan 15;2(1):e004564. doi: 10.1161/JAHA.112.004564.

11.

[Safety and effectiveness of combining clopidogrel and proton pump inhibitors].

Calderón Hernanz B, Pinteño Blanco M, Puigventos Latorre F, Martínez-López I.

Farm Hosp. 2009 Nov-Dec;33(6):338-9. Spanish. No abstract available.

PMID:
20038395
12.

Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.

Tsantes AE, Ikonomidis I, Papadakis I, Bonovas S, Gialeraki A, Kottaridi C, Kyriakou E, Kokori S, Douramani P, Kopterides P, Karakitsos P, Lekakis J, Kapsimali V.

Thromb Res. 2013 Aug;132(2):e105-11. doi: 10.1016/j.thromres.2013.06.015. Epub 2013 Jul 2.

PMID:
23830212
13.

Recent safety concerns with proton pump inhibitors.

Chen J, Yuan YC, Leontiadis GI, Howden CW.

J Clin Gastroenterol. 2012 Feb;46(2):93-114. doi: 10.1097/MCG.0b013e3182333820. Review.

PMID:
22227731
14.

Inhibition of the antithrombotic effects of clopidogrel by proton pump inhibitors: facts or fancies?

Lettino M.

Eur J Intern Med. 2010 Dec;21(6):484-9. doi: 10.1016/j.ejim.2010.08.004. Epub 2010 Sep 16. Review.

PMID:
21111931
15.

Effect of proton-pump inhibitors on the risk of lower gastrointestinal bleeding associated with NSAIDs, aspirin, clopidogrel, and warfarin.

Nagata N, Niikura R, Aoki T, Sakurai T, Moriyasu S, Shimbo T, Sekine K, Okubo H, Watanabe K, Yokoi C, Yanase M, Akiyama J, Uemura N.

J Gastroenterol. 2015 Nov;50(11):1079-86. doi: 10.1007/s00535-015-1055-2. Epub 2015 Feb 21.

PMID:
25700638
16.

Drug-drug interaction between clopidogrel and the proton pump inhibitors.

Norgard NB, Mathews KD, Wall GC.

Ann Pharmacother. 2009 Jul;43(7):1266-74. doi: 10.1345/aph.1M051. Epub 2009 May 26. Review.

PMID:
19470853
17.

The prevalence of co-administration of clopidogrel and proton pump inhibitors.

Shrestha K, Hughes JD, Lee YP, Parsons R.

Qual Prim Care. 2011;19(1):35-42.

PMID:
21703110
18.

Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.

Hsiao FY, Mullins CD, Wen YW, Huang WF, Chen PF, Tsai YW.

Pharmacoepidemiol Drug Saf. 2011 Oct;20(10):1043-9. doi: 10.1002/pds.2202. Epub 2011 Aug 8.

PMID:
21823195
19.

Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry.

Simon T, Steg PG, Gilard M, Blanchard D, Bonello L, Hanssen M, Lardoux H, Coste P, Lefèvre T, Drouet E, Mulak G, Bataille V, Ferrières J, Verstuyft C, Danchin N.

Circulation. 2011 Feb 8;123(5):474-82. doi: 10.1161/CIRCULATIONAHA.110.965640. Epub 2011 Jan 24.

20.

Analysis of gastrointestinal prophylaxis in patients receiving dual antiplatelet therapy with aspirin and clopidogrel.

Morneau KM, Reaves AB, Martin JB, Oliphant CS.

J Manag Care Pharm. 2014 Feb;20(2):187-93.

Supplemental Content

Support Center